➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
McKinsey
Colorcon
Baxter
Merck

Last Updated: July 25, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,795,604


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,795,604 protect, and when does it expire?

Patent 9,795,604 protects IMBRUVICA and is included in two NDAs.

This patent has twenty patent family members in thirteen countries.

Summary for Patent: 9,795,604
Title:Methods of treating and preventing graft versus host disease
Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventor(s): Byrd; John C. (Columbus, OH), Dubovsky; Jason A. (Columbus, OH), Muthusamy; Natarajan (Galloway, OH), Johnson; Amy Jo (Dublin, OH), Miklos; David (Stanford, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:14/523,650
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,795,604
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,795,604

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 AB RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 AB RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try it Free
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No ⤷  Try it Free ⤷  Try it Free TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,795,604

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 098208 ⤷  Try it Free
Australia 2014339815 ⤷  Try it Free
Australia 2020204270 ⤷  Try it Free
Canada 2928721 ⤷  Try it Free
Canada 3103411 ⤷  Try it Free
China 106102745 ⤷  Try it Free
China 111265531 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.